Summary of Study ST001405

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000955. The data can be accessed directly via it's Project DOI: 10.21228/M87X1R This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST001405
Study TitleMDM2-Dependent Rewiring of Metabolomic and Lipidomic Profiles in Dedifferentiated Liposarcoma Models
Study SummaryDedifferentiated liposarcoma (DDLPS) is an aggressive mesenchymal cancer marked by amplification of MDM2, an inhibitor of the tumor suppressor TP53. DDLPS patients with higher MDM2 amplification have lower chemotherapy sensitivity and worse outcome than patients with lower MDM2 amplification. We hypothesized that MDM2 amplification levels may be associated with changes in DDLPS metabolism. Six patient-derived DDLPS cell line models were subject to comprehensive metabolomic (Metabolon) and lipidomic (SCIEX 5600 TripleTOF-MS) profiling to assess associations with MDM2 amplification and their responses to metabolic perturbations. Comparing metabolomic profiles between MDM2 higher and lower amplification cells yielded a total of 23 differentially abundant metabolites across both panels (FDR < 0.05, log2 FC < 0.75), including ceramides, glycosylated ceramides, and sphingomyelins. Disruption of lipid metabolism through statin administration resulted in a chemo-sensitive phenotype in MDM2 lower cell lines only, suggesting that lipid metabolism may be a large contributor to the more aggressive nature of MDM2 higher DDLPS tumors. This study is the first to provide comprehensive metabolomic and lipidomic characterization of DDLPS cell lines and provides evidence for MDM2-dependent differential molecular mechanisms that are critical factors in chemoresistance and could thus affect patient outcome.
Institute
The Ohio State University
Last NamePatt
First NameAndrew
Address136 W. Pacemont Rd, Columbus, OH, 43202, USA
Emailpatt.14@osu.edu
Phone5183664293
Submit Date2020-05-22
Raw Data AvailableYes
Raw Data File Type(s)mzXML
Analysis Type DetailLC-MS
Release Date2020-07-07
Release Version1
Andrew Patt Andrew Patt
https://dx.doi.org/10.21228/M87X1R
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:

Factors:

Subject type: Cultured cells; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id Treatment_Status MDM2 Amplification Cell line
SA114059LIPNEG17MAR_56.10Atorvastatin Higher 141
SA114060LIPNEG17MAR_16.12Atorvastatin Higher 141
SA114061LIPPOS17MAR_56.10Atorvastatin Higher 141
SA114062LIPNEG17MAR_69.11Atorvastatin Higher 141
SA114063LIPPOS17MAR_16.12Atorvastatin Higher 141
SA114064LIPPOS17MAR_69.11Atorvastatin Higher 141
SA114065LIPNEG17MAR_60.84Atorvastatin Higher 224A
SA114066LIPPOS17MAR_60.84Atorvastatin Higher 224A
SA114067LIPPOS17MAR_04.83Atorvastatin Higher 224A
SA114068LIPPOS17MAR_77.82Atorvastatin Higher 224A
SA114069LIPNEG17MAR_83.83Atorvastatin Higher 224A
SA114070LIPNEG17MAR_77.82Atorvastatin Higher 224A
SA114071LIPNEG17MAR_33.47Atorvastatin Higher 246
SA114072LIPPOS17MAR_31.46Atorvastatin Higher 246
SA114073LIPPOS17MAR_33.47Atorvastatin Higher 246
SA114074LIPNEG17MAR_31.46Atorvastatin Higher 246
SA114075LIPNEG17MAR_59.48Atorvastatin Higher 246
SA114076LIPPOS17MAR_59.48Atorvastatin Higher 246
SA114077LIPNEG17MAR_32.119Atorvastatin Lower 224B
SA114078LIPPOS17MAR_15.118Atorvastatin Lower 224B
SA114079LIPPOS17MAR_76.120Atorvastatin Lower 224B
SA114080LIPNEG17MAR_15.118Atorvastatin Lower 224B
SA114081LIPNEG17MAR_76.120Atorvastatin Lower 224B
SA114082LIPPOS17MAR_32.119Atorvastatin Lower 224B
SA114083LIPNEG17MAR_57.155Atorvastatin Lower 815
SA114084LIPPOS17MAR_37.154Atorvastatin Lower 815
SA114085LIPPOS17MAR_58.156Atorvastatin Lower 815
SA114086LIPNEG17MAR_58.156Atorvastatin Lower 815
SA114087LIPPOS17MAR_57.155Atorvastatin Lower 815
SA114088LIPNEG17MAR_37.154Atorvastatin Lower 815
SA114089LIPPOS17MAR_11.191Atorvastatin Lower 863
SA114090LIPNEG17MAR_39.192Atorvastatin Lower 863
SA114091LIPPOS17MAR_39.192Atorvastatin Lower 863
SA114092LIPNEG17MAR_40.190Atorvastatin Lower 863
SA114093LIPPOS17MAR_40.190Atorvastatin Lower 863
SA114094LIPNEG17MAR_11.191Atorvastatin Lower 863
SA114095LIPPOS17MAR_63.POOL.4N/A N/A N/A
SA114096LIPPOS17MAR_81.BLANK.5N/A N/A N/A
SA114097LIPPOS17MAR_82.POOL.5N/A N/A N/A
SA114098LIPPOS17MAR_62.BLANK.4N/A N/A N/A
SA114099LIPPOS17MAR_20.BLANK.2N/A N/A N/A
SA114100LIPPOS17MAR_42.BLANK3N/A N/A N/A
SA114101LIPPOS17MAR_43.POOL.3N/A N/A N/A
SA114102LIPPOS17MAR_21.POOL.2N/A N/A N/A
SA114103LIPPOS17MAR_02.POOL.1N/A N/A N/A
SA114104LIPPOS17MAR_01.BLANK.1N/A N/A N/A
SA114105LIPNEG17MAR_42.BLANK3N/A N/A N/A
SA114106LIPNEG17MAR_43.POOL.3N/A N/A N/A
SA114107LIPNEG17MAR_01.BLANK.1N/A N/A N/A
SA114108LIPNEG17MAR_62.BLANK.4N/A N/A N/A
SA114109LIPNEG17MAR_63.POOL.4N/A N/A N/A
SA114110LIPNEG17MAR_89.BLANK.5N/A N/A N/A
SA114111LIPNEG17MAR_02.POOL.1N/A N/A N/A
SA114112LIPNEG17MAR_90.POOL.5N/A N/A N/A
SA114113LIPNEG17MAR_21.POOL.2N/A N/A N/A
SA114114LIPNEG17MAR_20.BLANK.2N/A N/A N/A
SA114115LIPPOS17MAR_52.3Untreated Higher 141
SA114116LIPNEG17MAR_52.3Untreated Higher 141
SA114117LIPPOS17MAR_47.1Untreated Higher 141
SA114118LIPPOS17MAR_71.2Untreated Higher 141
SA114119LIPNEG17MAR_47.1Untreated Higher 141
SA114120LIPNEG17MAR_71.2Untreated Higher 141
SA114121LIPPOS17MAR_12.74Untreated Higher 224A
SA114122LIPPOS17MAR_30.75Untreated Higher 224A
SA114123LIPPOS17MAR_07.73Untreated Higher 224A
SA114124LIPNEG17MAR_07.73Untreated Higher 224A
SA114125LIPNEG17MAR_12.74Untreated Higher 224A
SA114126LIPNEG17MAR_30.75Untreated Higher 224A
SA114127LIPPOS17MAR_09.38Untreated Higher 246
SA114128LIPNEG17MAR_27.37Untreated Higher 246
SA114129LIPPOS17MAR_27.37Untreated Higher 246
SA114130LIPNEG17MAR_09.38Untreated Higher 246
SA114131LIPNEG17MAR_84.39Untreated Higher 246
SA114132LIPPOS17MAR_05.39Untreated Higher 246
SA114133LIPNEG17MAR_53.109Untreated Lower 224B
SA114134LIPPOS17MAR_25.110Untreated Lower 224B
SA114135LIPNEG17MAR_10.111Untreated Lower 224B
SA114136LIPNEG17MAR_25.110Untreated Lower 224B
SA114137LIPPOS17MAR_10.111Untreated Lower 224B
SA114138LIPPOS17MAR_53.109Untreated Lower 224B
SA114139LIPPOS17MAR_51.145Untreated Lower 815
SA114140LIPPOS17MAR_72.147Untreated Lower 815
SA114141LIPNEG17MAR_72.147Untreated Lower 815
SA114142LIPNEG17MAR_51.145Untreated Lower 815
SA114143LIPNEG17MAR_18.146Untreated Lower 815
SA114144LIPPOS17MAR_18.146Untreated Lower 815
SA114145LIPPOS17MAR_38.183Untreated Lower 863
SA114146LIPNEG17MAR_70.182Untreated Lower 863
SA114147LIPPOS17MAR_67.181Untreated Lower 863
SA114148LIPNEG17MAR_38.183Untreated Lower 863
SA114149LIPPOS17MAR_70.182Untreated Lower 863
SA114150LIPNEG17MAR_67.181Untreated Lower 863
Showing results 1 to 92 of 92
  logo